Mandate

Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care

August 26, 2010

Vinge is advising Investor AB (publ) in connection with Investor’s agreement with Morgan Stanley Principal Investments to acquire Morgan Stanley’s 34 per cent equity stake in Mölnlycke Health Care Group AB. The purchase price amounts to EUR 510 million and following the transaction Investor will hold a 96 per cent equity stake. The remaining shares will be owned by Mölnlycke’s management and board.

Mölnlycke is a world leading manufacturer and provider of single-use surgical and wound care products and services, primarily for the professional healthcare sector. Investor together with Morgan Stanley originally invested in Mölnlycke in 2007.

Vinge’s team advising Investor consists of Ola Sandersson, Pontus Enquist, Dain Nevonen and Fredrik von der Esch. Johan Karlsson and Peter Alstegren are providing competiton law advice. Hans Wibom is the client relationship partner.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026